Gelonghui October 29th | Beihai Gofar Chuanshan Biological (600538.SH) announced that in the first three quarters of 2024, the revenue was 0.263 billion yuan, a decrease of 6.99% year-on-year; the net income attributable to the shareholders of the listed company was -20.8826 million yuan, with a basic earnings per share of -0.04 yuan.
国发股份(600538.SH)：前三季度净亏损2088.26万元
Beihai Gofar Chuanshan Biological (600538.SH): The net loss in the first three quarters was 20.8826 million yuan.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha